Andrew H Matthews
Overview
Explore the profile of Andrew H Matthews including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
125
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wang X, Gimotty P, Matthews A, Mamtani R, Luger S, Hexner E, et al.
Blood Adv
. 2025 Jan;
9(3):533-544.
PMID: 39888631
Little is known about the impact of recent advances in acute myeloid leukemia (AML) treatment on racial/ethnic disparities in survival outcomes. We performed a retrospective cohort study of patients with...
2.
Cardiotoxicity of venetoclax in patients with acute myeloid leukemia: comparison with anthracyclines
Onoue T, Matthews A, Vakilpour A, Kang Y, Lefebvre B, Smith A, et al.
Cardiooncology
. 2024 Nov;
10(1):75.
PMID: 39487530
Venetoclax is a promising drug for patients with acute myeloid leukemia (AML) ineligible for anthracycline-based treatments. In rats, venetoclax is reported to cause myocardial injury. Our objectives were to report...
3.
Connor M, Prathapa N, Frey N, Gill S, Hexner E, Bruno X, et al.
Haematologica
. 2024 Apr;
109(8):2732-2737.
PMID: 38634143
No abstract available.
4.
Laczko D, Poveda-Rogers C, Matthews A, Snaith O, Luger S, Bagg A, et al.
Leuk Lymphoma
. 2024 Mar;
65(7):958-964.
PMID: 38506144
The cohesin complex is a ring-shaped protein structure involved in DNA repair and chromosomal segregation. Studies have showed that genomic alterations in the cohesin complex members are among the initial...
5.
Abaza Y, Winer E, Guru Murthy G, Shallis R, Matthews A, Badar T, et al.
Am J Hematol
. 2024 Feb;
99(4):606-614.
PMID: 38342997
Venetoclax (VEN) combined with hypomethylating agents (HMAs) is the standard of care for the treatment of patients with newly diagnosed acute myeloid leukemia (AML) unfit for intensive chemotherapy. To date,...
6.
Matthews A, Perl A, Luger S, Gill S, Lai C, Porter D, et al.
Am J Hematol
. 2023 Jun;
98(8):1254-1264.
PMID: 37334852
Intensive chemotherapy with cytarabine and anthracycline (7&3) remains the standard therapy for patients medically fit for induction, but the assessment of fitness remains controversial. Venetoclax and hypomethylating agent (ven/HMA) combination...
7.
Matthews A, Pratz K, Carroll M
Cancers (Basel)
. 2022 Dec;
14(23).
PMID: 36497385
After forty years of essentially unchanged treatment in acute myeloid leukemia (AML), innovation over the past five years has been rapid, with nine drug approvals from 2016 to 2021. Increased...
8.
Matthews A, Perl A, Luger S, Loren A, Gill S, Porter D, et al.
Blood Adv
. 2022 May;
6(13):3997-4005.
PMID: 35507945
CPX-351 and venetoclax and azacitidine (ven/aza) are both indicated as initial therapy for acute myeloid leukemia (AML) in older adults. In the absence of prospective randomized comparisons of these regimens,...
9.
Oh D, Dinerman E, Matthews A, Aron A, Berg K
Case Rep Crit Care
. 2017 Jun;
2017:6148350.
PMID: 28620552
Background: Elevated lactate levels in critically ill patients are most often thought to be indicative of relative tissue hypoxia or type A lactic acidosis. Shock, severe anemia, and thromboembolic events...
10.
Goenka R, Matthews A, Zhang B, ONeill P, Scholz J, Migone T, et al.
J Exp Med
. 2013 Dec;
211(1):45-56.
PMID: 24367004
We have assessed the role of B lymphocyte stimulator (BLyS) and its receptors in the germinal center (GC) reaction and affinity maturation. Despite ample BLyS retention on B cells in...